<DOC>
	<DOCNO>NCT00506545</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , crossover , single center study SCH 619734 subject chronic cough unknown cause . Subjects randomize receive SCH 619734 placebo 7 day 7 day ' follow-up . After 6 week washout period , subject cross treatment . The primary objective evaluate effectiveness SCH 619734 reduce cough reflex sensitivity determine challenge capsaicin , agent induces cough .</brief_summary>
	<brief_title>Study Efficacy Safety SCH 619734 Subjects With Chronic Cough From Unknown Cause ( Study P04888 )</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<criteria>Male female subject , 18 &lt; 65 year old , history dry cough &gt; 6 month . By history , evaluation gastroesophageal reflux disease do rule minimum 8week trial antacid therapy ( protonpump inhibitor [ PPI ] give twice daily ) clinical response cough . By history , clinical sign symptom postnasal drip , sign symptom treat combination antihistamine decongestant minimum 8 week clinical response cough . By history , clinical sign symptom asthma , sign symptom treat combination inhale steroid shortacting betaagonist minimum 8 week clinical response cough . Subjects current evidence clinically significant pulmonary ( especially condition involve cough ) , hematopoietic , cardiovascular , hepatic , renal , neurologic , psychiatric , autoimmune , disease precludes subject 's participation study . In particular , diabetic , uncontrolled hypertensive , subject clinically significant cardiomyopathy , prostatic hypertrophy , glaucoma , seizure disorder , psychiatric disorder exclude participation study . Subjects asthma chronic obstructive pulmonary disease require chronic use inhale systemic corticosteroid . Subjects receive concurrent prohibit medication unless observe washout period prior baseline visit . These medication would include opioid nonopioidcontaining cough suppressant potent CYP3A inhibitor , ritonavir , ketoconazole , clarithromycin . Subjects receive ACE inhibitor MAOIs exclude study . Subjects history allergy two class medication . Current smoker , exsmokers stop smoke previous 6 month , subject cumulative smoke history &gt; 10 packyears exclude . ( Packyears way measure amount person smoke long period time . It calculate multiply number pack cigarettes smoked per day number year person smoke , eg , 10 packyear history equal smoking 1 pack per day 10 year 2 pack per day 5 year , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>